ARROWHEAD PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $27.24M.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $116.61M, a 51.69% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $46.83M.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $241.39M, a 43.77% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2025 was $241.39M, a 43.77% decline from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2024 was $429.26M.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2020 was $250.48M, a 313.87% increase from fiscal 2019.
- ARROWHEAD PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2019 was $60.52M, a 6.96% increase from fiscal 2018.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $27.24M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $116.61M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $46.83M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $241.39M 10-K · filed 2025-11-25 | |
| 2025-03-31 | $241.39M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $429.26M 10-K · filed 2025-11-25 | |
| 2024-03-31 | $429.26M 10-Q · filed 2025-08-07 | |
| 2020-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | $250.48M 10-K · filed 2022-11-28 |
| 2020-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-05 | $250.48M derived: sum of 4 quarters · filed 2021-11-22 |
| 2020-03-31 | $2.00K 10-Q · filed 2021-05-04 | $250.48M derived: sum of 4 quarters · filed 2021-11-22 |
| 2019-12-31 | $250.48M 10-Q · filed 2021-02-04 | $250.48M derived: sum of 4 quarters · filed 2021-11-22 |
| 2019-09-30 | -$729.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-22 | $60.52M 10-K · filed 2021-11-22 |
| 2019-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-05 | |
| 2019-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-07 | |
| 2018-12-31 | $60.52M 10-Q · filed 2020-02-05 | |
| 2018-09-30 | $56.59M 10-K · filed 2020-11-23 | |
| 2014-03-31 | $3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-05-06 | |
| 2013-12-31 | $2.43M 10-Q · filed 2014-02-04 | |
| 2013-09-30 | $2.05M 10-Q · filed 2014-05-06 | |
| 2012-09-30 | $10.35K derived: 10-Q 12 month − 10-Q 9 month · filed 2014-05-06 | $50.41K 10-Q · filed 2014-05-06 |
| 2012-06-30 | -$484.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-08-13 | $40.05K derived: sum of 4 quarters · filed 2014-05-06 |
| 2012-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-05-08 | |
| 2011-12-31 | $525.00K 10-Q · filed 2012-02-09 | |
| 2011-09-30 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2014-05-06 | $43.28K 10-Q · filed 2014-05-06 |
| 2010-09-30 | $1.07M 10-Q · filed 2014-05-06 | |
| 2009-09-30 | $2.76M 10-Q · filed 2012-08-13 | |
| 2006-09-30 | $1.08M 10-Q · filed 2012-08-13 | |
| 2005-09-30 | $50.00K 10-Q · filed 2014-05-06 | |
| 2004-09-30 | -$150.47K 10-Q · filed 2012-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |